文献速递心脑血管急症重症综合管理与镇静镇痛

实施高敏肌钙蛋白I检测与五年心肌梗死或死亡风险:阶梯楔形整群随机对照试验的观察性分析

Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial.
PubMed 文献 · BMJ · 2023-11-27
一句话结论疑似急性冠脉综合征患者实施高敏肌钙蛋白I检测后,被重新分类者五年心梗或死亡风险降低(校正HR 0.82,95%CI 0.72-0.94)。

该研究为阶梯楔形整群随机对照试验的二次观察性分析,纳入苏格兰10个二级和三级医疗中心的48 282例连续疑似急性冠脉综合征患者,医院随机分为早期(5家)或晚期(5家)实施高敏肌钙蛋白I检测(性别特异性诊断阈值:女性16 ng/L,男性34 ng/L)。主要终点为五年心肌梗死或死亡。全部患者中实施前后发生率29.4% vs 25.9%(校正HR 0.97,95%CI 0.93-1.01);被高敏检测重新分类者中63.0% vs 53.9%(0.82,0.72-0.94);非缺血性心肌损伤患者风险降低(0.83,0.75-0.91),而1型或2型心肌梗死患者无显著差异(分别为0.92,0.83-1.01和0.98,0.84-1.14)。作者认为获益主要见于被重新分类者,尤其是非缺血性心肌损伤患者。

要点

  • 在全部48 282例疑似急性冠脉综合征患者中,实施高敏肌钙蛋白I检测前后五年心梗或死亡发生率29.4% vs 25.9%,校正HR 0.97(95%CI 0.93-1.01),未达统计学显著。
  • 被高敏检测重新分类的1771例(占10 360例肌钙蛋白升高者的17.1%)中,五年心梗或死亡发生率63.0% vs 53.9%,校正HR 0.82(95%CI 0.72-0.94)。
  • 非缺血性心肌损伤患者实施高敏检测后五年心梗或死亡风险降低(校正HR 0.83,95%CI 0.75-0.91)。
  • 1型心肌梗死(校正HR 0.92,95%CI 0.83-1.01)和2型心肌梗死(校正HR 0.98,95%CI 0.84-1.14)患者未见显著获益。
  • 作者认为获益最显著见于非缺血性心肌损伤患者,提示高敏检测的益处超出识别心肌梗死本身。

适用人群与场景

  • 苏格兰10个二级和三级医疗中心的48 282例连续疑似急性冠脉综合征患者。
  • 心肌损伤定义为高敏肌钙蛋白I检测结果超过第99百分位(女性16 ng/L,男性34 ng/L)。

诊断标准与关键阈值

  • 心肌损伤:高敏肌钙蛋白I检测结果超过第99百分位,女性>16 ng/L,男性>34 ng/L。
  • 非缺血性心肌损伤、1型心肌梗死和2型心肌梗死按原文分类。

处置流程与药物剂量

  • 医院被随机分配为早期(n=5家医院)或晚期(n=5家医院)实施高敏肌钙蛋白I检测(采用性别特异性诊断阈值)。

研究设计与关键结果

  • 研究类型:阶梯楔形整群随机对照试验的二次观察性分析,纳入苏格兰10个二级和三级医疗中心48 282例连续疑似急性冠脉综合征患者,医院随机分为早期(5家)或晚期(5家)实施高敏肌钙蛋白I检测(性别特异性阈值:女性16 ng/L,男性34 ng/L)。
  • 10 360例患者肌钙蛋白浓度超过第99百分位,其中1771例(17.1%)被高敏检测重新分类。
  • 全部患者实施高敏检测前后五年心梗或死亡发生率:29.4%(5588/18 978) vs 25.9%(7591/29 304),校正HR 0.97(95%CI 0.93-1.01)。
  • 被高敏检测重新分类者实施前后五年心梗或死亡发生率:63.0%(456/720) vs 53.9%(567/1051),校正HR 0.82(95%CI 0.72-0.94)。
  • 非缺血性心肌损伤患者实施后五年心梗或死亡风险降低:校正HR 0.83(95%CI 0.75-0.91)。
  • 1型心肌梗死患者校正HR 0.92(95%CI 0.83-1.01),2型心肌梗死患者校正HR 0.98(95%CI 0.84-1.14),均未达统计学显著。

证据类型、等级与局限

  • 证据类型:阶梯楔形整群随机对照试验的二次观察性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在疑似急性冠脉综合征患者评估中实施高敏肌钙蛋白I检测与被重新分类者五年后续心肌梗死或死亡风险降低相关。
  • 作者认为,非缺血性心肌损伤患者结局改善最显著,提示获益超出识别心肌梗死本身。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov NCT01852123。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the impact of implementing a high sensitivity assay for cardiac troponin I on long term outcomes in patients with suspected acute coronary syndrome.

DESIGN: Secondary observational analysis of a stepped wedge, cluster randomised controlled trial.

SETTING: 10 secondary and tertiary care centres in Scotland, UK.

PARTICIPANTS: 48 282 consecutive patients with suspected acute coronary syndrome. Myocardial injury was defined as any high sensitivity assay result for cardiac troponin I >99th centile of 16 ng/L in women and 34 ng/L in men.

INTERVENTION: Hospital sites were randomly allocated to either early (n=5 hospitals) or late (n=5 hospitals) implementation of a high sensitivity cardiac troponin I assay with sex specific diagnostic thresholds.

MAIN OUTCOME MEASURE: The main outcome was myocardial infarction or death at five years.

RESULTS: 10 360 patients had cardiac troponin concentrations greater than the 99th centile, of whom 1771 (17.1%) were reclassified by the high sensitivity assay. The five year incidence of subsequent myocardial infarction or death before and after implementation of the high sensitivity assay was 29.4% (5588/18 978) v 25.9% (7591/29 304), respectively, in all patients (adjusted hazard ratio 0.97, 95% confidence interval 0.93 to 1.01), and 63.0% (456/720) v 53.9% (567/1051), respectively, in those reclassified by the high sensitivity assay (0.82, 0.72 to 0.94). After implementation of the high sensitivity assay, a reduction in subsequent myocardial infarction or death was observed in patients with non-ischaemic myocardial injury (0.83, 0.75 to 0.91) but not in those with type 1 or type 2 myocardial infarction (0.92, 0.83 to 1.01 and 0.98, 0.84 to 1.14).

CONCLUSIONS: Implementation of a high sensitivity cardiac troponin I assay in the assessment of patients with suspected acute coronary syndrome was associated with a reduced risk of subsequent myocardial infarction or death at five years in those reclassified by the high sensitivity assay. Improvements in outcome were greatest in patients with non-ischaemic myocardial injury, suggesting a broader benefit beyond the identification of myocardial infarction.

TRIAL REGISTRATION: ClinicalTrials.gov NCT01852123.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Lee KK, Doudesis D, Ferry AV, et al. Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial. BMJ. 2023. PMID: 38011922. doi:10.1136/bmj-2023-075009

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。